Effect of the acid suppressor omeprazole on the proliferation, migration, invasion and cell cycle of esophageal squamous cell carcinoma cells via the aryl hydrocarbon receptor pathway

Bai,Yu; Zhu,Peiyao; Zhou,Kun; Zhang,Shu-Guang

doi:10.3892/etm.2021.10621

Effect of the acid suppressor omeprazole on the proliferation, migration, invasion and cell cycle of esophageal squamous cell carcinoma cells via the aryl hydrocarbon receptor pathway

Authors:
- Yu Bai
- Peiyao Zhu
- Kun Zhou
- Shu-Guang Zhang
View Affiliations

Affiliations: Department of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: August 17, 2021 https://doi.org/10.3892/etm.2021.10621
Article Number: 1187
Copyright: © Bai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal cancer is a malignant tumor type with one of the highest mortality rates worldwide. The aryl hydrocarbon receptor (AHR), which has been investigated in recent years, has been confirmed to be associated with the occurrence and development of esophageal cancer. AHR has a variety of different ligands, which regulate its activity following binding. The widely known acid inhibitor omeprazole (OME) also affects AHR and its downstream proteins (such as the cytochrome P450 family) by non‑ligand binding; however, the mechanisms have remained to be fully elucidated. Therefore, the aim of the present study was to investigate the role of OME in esophageal squamous cell carcinoma (ESCC), whether the mechanism proceeds via the AHR pathway and how OME regulates AHR to affect the occurrence and development of esophageal carcinoma. The AHR‑selective regulator OME was used to treat the ESCC cell lines TE1 and KYSE150. Western blot analysis was used to verify the effect of OME on AHR and proliferating cell nuclear antigen (PCNA) protein expression levels, while Cell Counting Kit (CCK)‑8, wound‑healing and Transwell assays were used to determine the proliferation, migration and invasion of the ESCCs, respectively, following treatment with OME. In addition, flow cytometry was used to investigate the cell cycle distribution of the ESCCs following incubation with OME. AHR was highly expressed in the ESCCs and following treatment with OME, the protein expression levels of AHR and PCNA were downregulated. The CCK‑8 assay indicated that the proliferation of the ESCCs was also reduced following treatment with OME. Furthermore, flow cytometry revealed a notable block of the cells in G₁/G₀ phase, while the results of the wound‑healing and Transwell assays respectively suggested that cell migration and invasion were reduced. In conclusion, OME inhibited the proliferation, migration and invasion of ESCC cells and blocked the cell cycle via the AHR pathway, which may provide a therapeutic effect on esophageal squamous cell cancer.

View Figures

View References

1	Ilic M, Kocic S, Radovanovic D, Macuzic IZ and Ilic I: Trend in esophageal cancer mortality in Serbia, 1991-2015 (a population-based study): An age-period-cohort analysis and a joinpoint regression analysis. J BUON. 24:1233–1239. 2019.PubMed/NCBI
2	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.PubMed/NCBI View Article : Google Scholar
3	Malhotra G, Yanala U, Ravipati A, Follet M, Vijayakumar M and Are C: Global trends in esophageal cancer. J Surg Oncol. 115:564–579. 2017.PubMed/NCBI View Article : Google Scholar
4	Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M and Tanaka H: Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 23:233–242. 2013.PubMed/NCBI View Article : Google Scholar
5	Smyth E, Lagergren J, Fitzgerald R, Lordick F, Shah M, Lagergren P and Cunningham D: Oesophageal cancer. Nat Rev Dis primers. 3(17048)2017.PubMed/NCBI View Article : Google Scholar
6	Arnal MJ, Arenas ÁA and Arbeloa ÁL: Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 21:7933–7943. 2015.PubMed/NCBI View Article : Google Scholar
7	Schulte K, Green E, Wilz A, Platten M and Daumke O: Structural basis for aryl hydrocarbon receptor-mediated gene activation. Structure. 25:1025–1033. 2017.PubMed/NCBI View Article : Google Scholar
8	Wang F, Gao J, Mimura J, Kobayashi A, Sogawa K and Fujii-Kuriyama Y: Structure and expression of the mouse AhR nuclear translocator (mArnt) gene. J Biol Chem. 273:24867–24873. 1998.PubMed/NCBI View Article : Google Scholar
9	Nebert D: Aryl hydrocarbon receptor (AHR): ‘Pioneer member’ of the basic-helix/loop/helix per-Arnt-sim (bHLH/PAS) family of ‘sensors’ of foreign and endogenous signals. Prog Lipid Res. 67:38–57. 2017.PubMed/NCBI View Article : Google Scholar
10	Shiizaki K, Ohsako S, Kawanishi M and Yagi T: Omeprazole alleviates benzo[a]pyrene cytotoxicity by inhibition of CYP1A1 activity in human and mouse hepatoma cells. Basic Clin Pharmacol Toxicol. 103:468–475. 2008.PubMed/NCBI View Article : Google Scholar
11	Gao W, Li HY, Wang LX, Hao LJ, Gao JL, Zheng RJ, Cai CJ and Si YL: Protective effect of omeprazole on gastric mucosal of cirrhotic portal hypertension rats. Asian Pac J Trop Med. 7:402–406. 2014.PubMed/NCBI View Article : Google Scholar
12	Weil J, Bell GD, Powell K, Morden A, Harrison G, Gant PW, Jones PH and Trowell JE: Omeprazole and helicobacter pylori: Temporary suppression rather than true eradication. Aliment Pharmacol Ther. 5:309–313. 1991.PubMed/NCBI View Article : Google Scholar
13	Blum R: Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health Syst Pharm. 53:1401–1415. 1996.PubMed/NCBI View Article : Google Scholar
14	Jin UH, Lee SO and Safe S: Aryl hydrocarbon receptor (AHR)-active pharmaceuticals are selective AHR modulators in MDA-MB-468 and BT474 breast cancer cells. J Pharmacol Exp Ther. 343:333–341. 2012.PubMed/NCBI View Article : Google Scholar
15	Nguyen LP and Bradfield CA: The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol. 21:102–116. 2008.PubMed/NCBI View Article : Google Scholar
16	Jin UH, Kim SB and Safe S: Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway. Chem Res Toxicol. 28:907–918. 2015.PubMed/NCBI View Article : Google Scholar
17	Murray IA, Patterson AD and Perdew GH: Aryl hydrocarbon receptor ligands in cancer: Friend and foe. Nat Rev Cancer. 14:801–814. 2014.PubMed/NCBI View Article : Google Scholar
18	Patrizi B and Siciliani de Cumis M: TCDD toxicity mediated by epigenetic mechanisms. Int J Mol Sci. 19(4101)2018.PubMed/NCBI View Article : Google Scholar
19	Opitz C, Litzenburger U, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, et al: An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 478:197–203. 2011.PubMed/NCBI View Article : Google Scholar
20	Huang H: Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: Recent advances. Sensors (Basel). 18(3249)2018.PubMed/NCBI View Article : Google Scholar
21	Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.PubMed/NCBI View Article : Google Scholar
22	Jankowski JAZ, de Caestecker J, Love SB, Reilly G, Watson P, Sanders S, Ang Y, Morris D, Bhandari P, Brooks C, et al: Esomeprazole and aspirin in Barrett's oesophagus (AspECT): A randomised factorial trial. Lancet. 392:400–408. 2018.PubMed/NCBI View Article : Google Scholar
23	Shiizaki K, Kido K and Mizuta Y: Insight into the relationship between aryl-hydrocarbon receptor and β-catenin in human colon cancer cells. PLoS One. 14(e0224613)2019.PubMed/NCBI View Article : Google Scholar
24	Tomblin JK, Arthur S, Primerano DA, Chaudhry AR, Fan J, Denvir J and Salisbury TB: Aryl hydrocarbon receptor (AHR) regulation of L-type amino acid transporter 1 (LAT-1) expression in MCF-7 and MDA-MB-231 breast cancer cells. Biochem Pharmacol. 106:94–103. 2016.PubMed/NCBI View Article : Google Scholar
25	Donovan M, Selmin O and Romagnolo D: Aryl hydrocarbon receptor diet and breast cancer risk. Yale J Biol Med. 91:105–127. 2018.PubMed/NCBI
26	Terashima J, Jimma Y, Jimma K, Hakata S, Yachi M, Habano W and Ozawa S: The regulation mechanism of AhR activated by benzo[a]pyrene for CYP expression are different between 2D and 3D culture of human lung cancer cells. Drug Metab Pharmacokinet. 33:211–214. 2018.PubMed/NCBI View Article : Google Scholar
27	Gao H, Ye G, Lin Y, Chi Y and Dong S: Benzo[a]pyrene at human blood equivalent level induces human lung epithelial cell invasion and migration via aryl hydrocarbon receptor signaling. J Appl Toxicol. 40:1087–1098. 2020.PubMed/NCBI View Article : Google Scholar
28	Dong S, Zhu P and Zhang S: Expression of collagen type 1 alpha 1 indicates lymph node metastasis and poor outcomes in squamous cell carcinomas of the lung. PeerJ. 8(e10089)2020.PubMed/NCBI View Article : Google Scholar
29	Yoshinari K, Ueda R, Kusano K, Yoshimura T, Nagata K and Yamazoe Y: Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. Biochem Pharmacol. 76:139–145. 2008.PubMed/NCBI View Article : Google Scholar
30	Vogeley C, Esser C, Tüting T, Krutmann J and Haarmann-Stemmann T: Role of the aryl hydrocarbon receptor in environmentally induced skin aging and skin carcinogenesis. Int J Mol Sci. 20(6005)2019.PubMed/NCBI View Article : Google Scholar
31	Chen Z, Cai A, Zheng H, Huang H, Sun R, Cui X, Ye W, Yao Q, Chen R and Kou L: Carbidopa suppresses prostate cancer via aryl hydrocarbon receptor-mediated ubiquitination and degradation of androgen receptor. Oncogenesis. 9(49)2020.PubMed/NCBI View Article : Google Scholar
32	Wang L, Tang W, Yang S, He P, Wang J, Gaedcke J, Ströbel P, Azizian A, Ried T, Gaida MM, et al: NO /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer. Int J Cancer. 146:3160–3169. 2020.PubMed/NCBI View Article : Google Scholar
33	Masoudi S, Nemati AH, Fazli HR, Beygi S, Moradzadeh M, Pourshams A and Mohamadkhani A: An increased level of aryl hydrocarbon receptor in patients with pancreatic cancer. Middle East J Dig Dis. 11:38–44. 2019.PubMed/NCBI View Article : Google Scholar
34	Zhu P, Yu H, Zhou K, Bai Y, Qi R and Zhang S: 3,3'-Diindolylmethane modulates aryl hydrocarbon receptor of esophageal squamous cell carcinoma to reverse epithelial-mesenchymal transition through repressing RhoA/ROCK1-mediated COX2/PGE2 pathway. J Exp Clin Cancer Res. 39(113)2020.PubMed/NCBI View Article : Google Scholar
35	Zhu P, Zhou K, Lu S, Bai Y, Qi R and Zhang S: Modulation of aryl hydrocarbon receptor inhibits esophageal squamous cell carcinoma progression by repressing COX2/PGE2/STAT3 axis. J Cell Commun Signal. 14:175–192. 2020.PubMed/NCBI View Article : Google Scholar